METHOD AND KIT FOR DISTINGUISHING BETWEEN PROSTATE CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA
The present invention addresses the problem of providing a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using an analyte sample in a small amount. The method for distinguishing between prostate carcinoma and beni...
Gespeichert in:
Hauptverfasser: | , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; jpn |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present invention addresses the problem of providing a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using an analyte sample in a small amount. The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia according to the present invention, which is a solution for the problem, is as follows: an analyte sample containing a prostate-specific antigen (PSA) is brought into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby causing the binding of a free PSA to the anti-free PSA antibody immobilized on the carrier; the carrier in which the free PSA has been bound to the immobilized anti-free PSA antibody is brought into contact with a monoclonal antibody capable of specifically recognizing a sugar chain in which a terminal sialic acid residue is bound to galactose via an α(2,3) bond, thereby causing the binding of the monoclonal antibody capable of specifically recognizing the sugar chain in which the terminal sialic acid residue has been bound to galactose via an α(2,3) bond to the free PSA that has been bound to the anti-free PSA antibody immobilized on the carrier; the amount of the free PSA that has an N-type sugar chain in which the terminal sialic acid residue has been bound to galactose via an α(2,3) bond is measured; and subsequently the amount measured in the proceeding step is compared with a preset cut-off value for prostate carcinoma and benign prostatic hyperplasia. When the measured amount is larger than the cut-off value, it is determined that prostate carcinoma is developed or the probability of prostate carcinoma is high. When the measured amount is smaller than the cut-off value, it is determined that benign prostatic hyperplasia is developed or the probability of benign prostatic hyperplasia is high.
La présente invention aborde le problème consistant à fournir une méthode permettant de distinguer, avec une sensibilité élevée et une bonne reproductibilité, un cancer prostatique d'une hypertrophie bénigne de la prostate à l'aide d'un échantillon d'analyte de faible quantité. La méthode permettant de distinguer un cancer prostatique d'une hypertrophie bénigne de la prostate selon la présente invention, et qui constitue la solution au problème susmentionné, est comme suit : un échantillon d'analyte contenant un antigène spécifique de la prostate (PSA) est mis en contact avec un support sur leque |
---|